Voyager Therapeutics, Inc. (NASDAQ:VYGR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) have been assigned a consensus recommendation of “Moderate Buy” from the six ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $13.75.

Several brokerages have recently issued reports on VYGR. Wall Street Zen upgraded shares of Voyager Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Wedbush reissued an “outperform” rating and issued a $8.00 target price on shares of Voyager Therapeutics in a research report on Tuesday, November 11th. Finally, HC Wainwright dropped their price target on Voyager Therapeutics from $30.00 to $25.00 and set a “buy” rating on the stock in a research report on Wednesday, November 12th.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, CEO Alfred Sandrock sold 12,192 shares of Voyager Therapeutics stock in a transaction dated Tuesday, February 10th. The stock was sold at an average price of $3.78, for a total transaction of $46,085.76. Following the completion of the transaction, the chief executive officer owned 509,989 shares of the company’s stock, valued at $1,927,758.42. The trade was a 2.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 20,286 shares of company stock valued at $77,248 in the last three months. 6.39% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently added to or reduced their stakes in VYGR. Bank of Montreal Can bought a new position in shares of Voyager Therapeutics in the second quarter worth approximately $36,000. Wexford Capital LP purchased a new position in Voyager Therapeutics in the 3rd quarter worth approximately $42,000. ProShare Advisors LLC bought a new position in shares of Voyager Therapeutics in the 4th quarter worth $44,000. CIBC Asset Management Inc purchased a new stake in shares of Voyager Therapeutics during the 4th quarter valued at $45,000. Finally, R Squared Ltd purchased a new stake in shares of Voyager Therapeutics during the 2nd quarter valued at $48,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Stock Down 0.9%

VYGR stock opened at $3.39 on Friday. The firm has a market cap of $188.48 million, a PE ratio of -1.57 and a beta of 1.30. The business has a 50 day moving average of $3.99 and a 200-day moving average of $4.09. Voyager Therapeutics has a 12-month low of $2.64 and a 12-month high of $5.55.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.